Abstract
Background: Heterocyclic system is a common structure feature of widely used drugs such as anticancer, anticonvulsant, antieplipeptic, and antiparastic agents.
Methods: Structure-based drug design and Glide docking studies were employed to rationalize the toxicity of a new series of thiosemicarbazone-based indole derivatives against human colon carcinoma (HCT116) cell line.
Results: Glide docking studies showed that the verified compounds fit PI3Kα kinase catalytic site and form H-bonding with K802, Y836, V851, S854, Q859, S919, and D933. The pharmacophore modeling of PI3Kα active inhibitors displayed that verified compounds matched four out of five functionalities of PI3Kα inhibitors.
Conclusion: Our findings suggest that further optimization of the core structure of this series would be beneficial for colon cancer treatment.
Keywords: PI3Kα, glide docking, pharmacophore screening, HCT-116, thiosemicarbazone-based indoles, DNA, RNA.
Letters in Drug Design & Discovery
Title:Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors
Volume: 14 Issue: 11
Author(s): Dima A. Sabbah*Kamal Sweidan
Affiliation:
- Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733,Jordan
Keywords: PI3Kα, glide docking, pharmacophore screening, HCT-116, thiosemicarbazone-based indoles, DNA, RNA.
Abstract: Background: Heterocyclic system is a common structure feature of widely used drugs such as anticancer, anticonvulsant, antieplipeptic, and antiparastic agents.
Methods: Structure-based drug design and Glide docking studies were employed to rationalize the toxicity of a new series of thiosemicarbazone-based indole derivatives against human colon carcinoma (HCT116) cell line.
Results: Glide docking studies showed that the verified compounds fit PI3Kα kinase catalytic site and form H-bonding with K802, Y836, V851, S854, Q859, S919, and D933. The pharmacophore modeling of PI3Kα active inhibitors displayed that verified compounds matched four out of five functionalities of PI3Kα inhibitors.
Conclusion: Our findings suggest that further optimization of the core structure of this series would be beneficial for colon cancer treatment.
Export Options
About this article
Cite this article as:
Sabbah A. Dima *, Sweidan Kamal , Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors, Letters in Drug Design & Discovery 2017; 14 (11) . https://dx.doi.org/10.2174/1570180814666170619112647
DOI https://dx.doi.org/10.2174/1570180814666170619112647 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NAD in Skin: Therapeutic Approaches for Niacin
Current Pharmaceutical Design Clinical Management of Secretion Retention in Critically Ill Patients who are Intubated and Mechanically Ventilated
Current Respiratory Medicine Reviews Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Relevance of an Academic GMP Pan-European Vector Infra-Structure (PEVI)
Current Gene Therapy Multiple Forms of Human DNA Polymerase Delta Sub-Assembling in Cellular DNA Transactions
Current Protein & Peptide Science Comparative Analysis of Fruit and Vegetable Consumption in a Food Service Unit: Is it Possible to Influence the Choices?
The Natural Products Journal Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Nanocarriers(s) Based Approaches in Cancer Therapeutics
Current Nanomedicine Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Characteristics of Peripheral Blood Stem Cells: 2D-Gel Electrophoresis and Kinetic Parameter of Exocytosis
Current Biomarkers (Discontinued) HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer
Current Medicinal Chemistry Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy G4-Interacting DNA Helicases and Polymerases: Potential Therapeutic Targets
Current Medicinal Chemistry